These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia. Motta I; Allice T; Romito A; Ferrara M; Ecclesia S; Imperiale D; Ghisetti V; Di Perri G; Bonora S; Calcagno A Antivir Ther; 2017; 22(6):539-543. PubMed ID: 28198350 [TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen. Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168 [TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid viral load, virus isolation, and intrathecal immunoactivation in HIV type 2 infection. Arvidson N; Gisslén M; Albert J; Brandin E; Svennerholm B; Fuchs D; Hagberg L AIDS Res Hum Retroviruses; 2004 Jul; 20(7):711-5. PubMed ID: 15307916 [TBL] [Abstract][Full Text] [Related]
12. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699 [TBL] [Abstract][Full Text] [Related]
13. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Canestri A; Lescure FX; Jaureguiberry S; Moulignier A; Amiel C; Marcelin AG; Peytavin G; Tubiana R; Pialoux G; Katlama C Clin Infect Dis; 2010 Mar; 50(5):773-8. PubMed ID: 20100092 [TBL] [Abstract][Full Text] [Related]
14. Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. Abdulle S; Hagberg L; Svennerholm B; Fuchs D; Gisslén M AIDS; 2002 Nov; 16(16):2145-9. PubMed ID: 12409735 [TBL] [Abstract][Full Text] [Related]
15. Discordant CSF/plasma HIV-1 RNA in individuals on virologically suppressive antiretroviral therapy in Western India. Dravid AN; Natrajan K; Kulkarni MM; Saraf CK; Mahajan US; Kore SD; Rathod NM; Mahajan US; Wadia RS Medicine (Baltimore); 2018 Feb; 97(8):e9969. PubMed ID: 29465595 [TBL] [Abstract][Full Text] [Related]
16. Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study. García F; Alonso MM; Romeu J; Knobel H; Arrizabalaga J; Ferrer E; Dalmau D; Ruiz I; Vidal F; Frances A; Segura F; Gomez-Sirvent JL; Cruceta A; Clotet B; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM J Acquir Immune Defic Syndr; 2000 Sep; 25(1):26-35. PubMed ID: 11064501 [TBL] [Abstract][Full Text] [Related]
17. Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals--correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels. Andersson LM; Hagberg L; Fuchs D; Svennerholm B; Gisslén M J Neurovirol; 2001 Dec; 7(6):542-7. PubMed ID: 11704886 [TBL] [Abstract][Full Text] [Related]